View in browser Key highlights from 2023 SenzaGen has had another dynamic and successful year in 2023, actively advancing our vision of replacing animal testing with innovative methods that more accurately reflect human biology. Below is a snapshot of key events from this year.  Industry leader adopts ethical alternatives to animal testing SenzaGen was recently selected to test substances for yet another new customer, a global industry leader. The assignment comprises non-animal tests for skin sensitization, including SenzaGen’s highly performing test platform, GARD®skin. Read more about the collaboration ALTEX Journal:  "Challenges integrating skin sensitization data for assessment of difficult-to-test substances" ExxonMobil The recently published article by ExxonMobil focuses on the challenges of determining skin sensitization hazard in the case of difficult-to-test substances with conflicting or low-confidence data, where GARD®skin data on UVCBs and hydrophobic substances provides valuable input for the integrated hazard assessment. The article provides new peer-reviewed evidence for the applicability domain of GARD®skin on UVCBs, hydrophobic and highly complex substances. Read the full article Scientific collaborations: Extended applicability and quantitative potency assessment Our collaborations with industry partners led to the development of exciting projects and the generation of new scientific data. Throughout the year, the broad applicability of the GARD® assays was showcased in various posters and presentations.    📍 Corteva Agriscience | agrochemical formulations Joint poster: GARD®: a study to investigate the applicability domain for agrochemical formulations 📍 Johnson Matthey | metals Joint poster: Applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals 📍 ExxonMobil | UVCBs Joint poster: The Utility of GARDskin to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products 📍 IFF and RIFM | fragrances, PoD          Joint poster: GARD®skin Dose-Response assay for PoD determination of fragrance materials and its application in conducting Quantitative Risk Assessment (QRA) 📍 Takasago | fragrances, NESIL values      Joint poster: A case study on using the GARD®skin Dose-Response assay to derive NESIL values for novel fragrance ingredients for confirmatory human patch studies 📍 Duearity | medical devices     Case study: Using in vitro data in your CE marking submission of Medical Devices 📍 RIFM | photosensitization, fragrance safety Featured article: GARD®skin assay offers unprecedented ‘potential way forward’ to test photosensitivity, says RIFM principal scientist Expanded GARD availability We are expanding our distributor network to meet the increasing demand for in vitro toxicology and our innovative GARD® test portfolio. Collaborations with specialist CROs develop access to our services. We are excited to welcome GV Research Platform (GVRP) in India and Oroxcell in France as our latest partners.  SenzaGen ranked one of Sweden’s fastest-growing technology companies With a remarkable 1433% growth rate over the last four years, SenzaGen ranks 18th on Deloitte's Sweden Technology Fast 50, a testament to our pioneering work in technology and innovation.  Find out more about the award Upcoming events 🌎 2024 SOT Mar 10-14 | Salt lake city, USA | Booth: #732 🌎 2024 ESTIV Jun 3-6 | Prague, Czech Republic  🌎 2024 Eurotox Sep 8-11 | Copenhagen, Denmark Copyright © SenzaGen 2023. All rights reserved. SenzaGen AB | Medicon Village | 223 81 Lund, Sweden You are receiving this email because you expressed interest in SenzaGen's technology in the past. Unsubscribe here if you do not wish to receive technology updates and news from us.